Aauracare Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
as on 17-12-2024
- Paid Up Capital ₹ 0.30 M
as on 17-12-2024
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 5.57%
(FY 2017)
- Profit 50.54%
(FY 2017)
- Ebitda 128.33%
(FY 2017)
- Net Worth 92.53%
(FY 2017)
- Total Assets 67.41%
(FY 2017)
About Aauracare Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Atul Jain, Tashi Wangdi, and Ningma Doma serve as directors at the Company.
- CIN/LLPIN
U24232DL2011PTC219628
- Company No.
219628
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 May 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Aauracare Pharmaceutical Private Limited offer?
Aauracare Pharmaceutical Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules.
Who are the key members and board of directors at Aauracare Pharmaceutical?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atul Jain  | Director | 23-May-2011 | Current |
| Tashi Wangdi | Director | 23-May-2011 | Current |
| Ningma Doma | Director | 07-Jan-2012 | Current |
Financial Performance of Aauracare Pharmaceutical.
Aauracare Pharmaceutical Private Limited, for the financial year ended 2017, experienced modest growth in revenue, with a 5.57% increase. The company also saw a substantial improvement in profitability, with a 50.54% increase in profit. The company's net worth Soared by an impressive increase of 92.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aauracare Pharmaceutical?
In 2017, Aauracare Pharmaceutical had a promoter holding of 66.67% and a public holding of 33.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Samye Consumers Products Private LimitedActive 4 years 6 monthsAtul Jain and Ningma Doma are mutual person
- Aauracare Healthcare Private LimitedActive 1 year 9 months
Atul Jain and Ningma Doma are mutual person
- Samye Pharmaceuticals Private LimitedActive 5 years 7 months
Atul Jain, Tashi Wangdi and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aauracare Pharmaceutical?
Unlock and access historical data on people associated with Aauracare Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aauracare Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aauracare Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
